Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Uncovering Mitochondrial Determinants of Racial Disparities in Ovarian Cancer.

Literature DB >> 33246874

Uncovering Mitochondrial Determinants of Racial Disparities in Ovarian Cancer.

Abstract

Ovarian cancer (OC) incidence and mortality rates differ between racial groups. Mitochondrial genetic factors are now emerging as determinants of racial disparities in OC. A comprehensive understanding of the role of mitochondria in OC health disparities will help in developing novel therapeutic strategies targeting mitochondria to reduce or eliminate racial health disparities.

Entities: Chemical

Keywords: mitochondria; mitochondrial genetic factors; ovarian cancer; racial disparity; racial groups; therapeutic strategies

Mesh：

Year: 2020 PMID： 33246874 PMCID： PMC9375692 DOI： 10.1016/j.trecan.2020.10.014

Source DB: PubMed Journal: Trends Cancer ISSN： 2405-8025

15 in total

Review 1. Role of diets rich in omega-3 and omega-6 in the development of cancer.

Authors: Sara Huerta-Yépez; Ana B Tirado-Rodriguez; Oliver Hankinson
Journal: Bol Med Hosp Infant Mex Date: 2016-11-30

Review 2. Mitochondrial determinants of cancer health disparities.

Authors: Aaheli Roy Choudhury; Keshav K Singh
Journal: Semin Cancer Biol Date: 2017-05-06 Impact factor: 15.707

3. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

Authors: Iris L Romero; Anna McCormick; Kelsey A McEwen; SeoYoung Park; Theodore Karrison; S Diane Yamada; Silvana Pannain; Ernst Lengyel
Journal: Obstet Gynecol Date: 2012-01 Impact factor: 7.661

4. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.

Authors: Thea Eline Hetland; Dag Andre Nymoen; Elisabeth Emilsen; Janne Kærn; Claes G Tropé; Vivi Ann Flørenes; Ben Davidson
Journal: Gynecol Oncol Date: 2012-05-28 Impact factor: 5.482

5. Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.

Authors: Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi
Journal: Clin Cancer Res Date: 2016-08-12 Impact factor: 12.531

6. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.

Authors: N L Chamberlain; E D Driver; R L Miesfeld
Journal: Nucleic Acids Res Date: 1994-08-11 Impact factor: 16.971

7. Natural selection shaped regional mtDNA variation in humans.

Authors: Dan Mishmar; Eduardo Ruiz-Pesini; Pawel Golik; Vincent Macaulay; Andrew G Clark; Seyed Hosseini; Martin Brandon; Kirk Easley; Estella Chen; Michael D Brown; Rem I Sukernik; Antonel Olckers; Douglas C Wallace
Journal: Proc Natl Acad Sci U S A Date: 2002-12-30 Impact factor: 11.205

Review 2. Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.

Authors: Balaraman Kalyanaraman
Journal: FASEB J Date: 2022-04 Impact factor: 5.834

2 in total

Uncovering Mitochondrial Determinants of Racial Disparities in Ovarian Cancer.

Review 1. Role of diets rich in omega-3 and omega-6 in the development of cancer.

Review 2. Mitochondrial determinants of cancer health disparities.

3. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

4. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.

5. Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.

6. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.

7. Natural selection shaped regional mtDNA variation in humans.

8. Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics.

9. MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2.

10. Circulating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer.

Review 1. The mitochondrial landscape of ovarian cancer: emerging insights.

Review 2. Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.